Bumrungrad reported mixed 2Q24 performance with revenue up 3% YoY, but bottomline growth outpaced revenue. International patient revenue contribution remained stable but lower than pre-COVID levels.
What is covered in the Full Insight:
Mixed Performance in 2Q24
Revenue and Profit Growth
International Patient Revenue Analysis
Comparison with BDMS
Future Prospects and Competition
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.